Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
| ▸ | PRKDC | P78527 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | GCGR | P47871 | 1/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | SCN4A | P35499 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16855883 | 0.88 | MAPK13 (0.44) | DHODHMAOBCHEK2MAPK13GCGR | |
| SCHEMBL6502581 | 0.85 | LTA4H (0.49) | DHODHCHEK2PIK3CDPIK3CAPIK3CB | |
| SCHEMBL9135156 | 0.83 | GAA (0.49) | DHODHMAOBCHEK2PIK3CDPIK3CA | |
| SCHEMBL703677 | 0.82 | DCUN1D1 (0.54) | NR1H2NR1H3TSHRRAB9AGAA | |
| SCHEMBL4655029 | 0.81 | GP6 (0.49) | NPC1GAA | |
| SCHEMBL704303 | 0.81 | MAOB (0.51) | DHODHMAOBPIK3CDPIK3CAPIK3CB | |
| SCHEMBL12761250 | 0.80 | GP6 (0.37) | TSHRNPC1RAB9AGAADCUN1D1 | |
| SCHEMBL6961454 | 0.79 | GP6 (0.49) | MAOBLTA4HNPC1RAB9AFFAR1 | |
| SCHEMBL1250174 | 0.79 | GSTP1 (0.48) | DHODHMAOBPIK3CDPIK3CAPIK3CB | |
| SCHEMBL6961450 | 0.79 | MAOA (0.44) | MAOBNR1H2NR1H3FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411385-A1 | NOVEL HETEROARYL BUTANOIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2022-12-29 | — | — | US | disclosed |
| US-20220411385-A1 | NOVEL HETEROARYL BUTANOIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2022-12-29 | — | — | US | disclosed |
| WO-2022202414-A1 | PROTECTIVE TAPE, SEMICONDUCTOR PROTECTIVE TAPE, AND METHOD FOR PRODUCING SEMICONDUCTOR DEVICE | 積水化学工業株式会社 | 2022-09-29 | — | — | WO | disclosed |
| WO-2022202414-A1 | PROTECTIVE TAPE, SEMICONDUCTOR PROTECTIVE TAPE, AND METHOD FOR PRODUCING SEMICONDUCTOR DEVICE | 積水化学工業株式会社 | 2022-09-29 | — | — | WO | disclosed |
| US-20210340112-A1 | NOVEL HETEROARYL BUTANOIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2021-11-04 | — | — | US | disclosed |
| EP-3083564-B1 | HETEROARYL BUTANOIC ACID DERIVATIVES AS LTA4H INHIBITORS | NOVARTIS AG (CH) | 2018-07-11 | — | — | EP | disclosed |
| EP-3083564-B1 | HETEROARYL BUTANOIC ACID DERIVATIVES AS LTA4H INHIBITORS | NOVARTIS AG (CH) | 2018-07-11 | — | — | EP | disclosed |
| US-20180170887-A1 | NOVEL HETEROARYL BUTANOIC ACID DERIVATIVES | NOVARTIS PHARMA AG (CH) | 2018-06-21 | — | — | US | disclosed |
| US-20180170887-A1 | NOVEL HETEROARYL BUTANOIC ACID DERIVATIVES | NOVARTIS PHARMA AG (CH) | 2018-06-21 | — | — | US | disclosed |
| US-9981926-B2 | Heteroaryl butanoic acid derivatives | NOVARTIS AG (CH) | 2018-05-29 | — | — | US | disclosed |
| US-7601709-B2 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| EP-1590442-A4 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2007-07-18 | — | — | EP | disclosed |
| CN-1771050-A | macrocyclic inhibitors of hepatitis c serine protease | ENANTA PHARM INC (US) | 2006-05-10 | — | — | CN | disclosed |
| EP-1590442-A3 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2005-11-03 | — | — | EP | disclosed |
| EP-1590442-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20050153877-A1 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| WO-2004072243-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| US-4145557-A | ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIPYRETICS | ELI LILLY AND COMPANY (US) | 1979-03-20 | — | — | US | disclosed |
| US-4001322-A | ANTIINFLAMMATORY, ANALGESIC, ANTIPYRETIC | ELI LILLY AND COMPANY (US) | 1977-01-04 | — | — | US | disclosed |
| US-3972934-A | ANTIINFLAMMATORY, ANALGESIC, ANTIPYRETIC | ELI LILLY AND COMPANY (US) | 1976-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411385-A1 | NOVEL HETEROARYL BUTANOIC ACID DERIVATIVES | LTA4H, LTC4S, LTB4R | DHODH 205/4885MAOB 664/4885CHEK2 4751/4885 |
| US-20180170887-A1 | NOVEL HETEROARYL BUTANOIC ACID DERIVATIVES | LTA4H, LTC4S, LTB4R | DHODH 205/4885MAOB 664/4885CHEK2 4751/4885 |
| US-20050153877-A1 | Macrocyclic hepatitis C serine protease inhibitors | PRSS1, SPINT2, TMPRSS4 | DHODH 2030/4885MAOB 1631/4885CHEK2 3955/4885 |
| US-20210340112-A1 | NOVEL HETEROARYL BUTANOIC ACID DERIVATIVES | LTA4H, LTC4S, LTB4R | DHODH 205/4885MAOB 664/4885CHEK2 4751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.